Triple Negative Breast Cancer News and Research

RSS

New approach to combat cancer by reactivating natural RNA kill switch

Alternative RNA splicing is like a movie editor cutting and rearranging scenes from the same footage to create different versions of a film.

14 Mar 2025

Decoding programmed cell death in breast cancer

This review highlights the critical role of ubiquitin-specific proteases (USPs) in regulating programmed cell death (PCD) in breast cancer (BC). As the most prevalent malignant tumor among women, BC remains a significant global health challenge.

11 Mar 2025

Diabetes changes the biology of breast cancer, study shows

More than 120 million Americans suffer from diabetes or pre-diabetes. Triple-negative breast cancer (TNBC) is the most aggressive form of breast cancer, and TNBC patients with obesity-driven diabetes often have worse outcomes.

6 Mar 2025

Unveiling the role of FAM20C in disease and cancer treatment

A new review published in Genes & Diseases explores the multifaceted role of FAM20C, a Golgi protein kinase, in disease progression.

23 Feb 2025

New computational tool iDOMO improves prediction of drug synergy

Researchers at the Icahn School of Medicine at Mount Sinai have developed a powerful computational tool, named iDOMO, to improve the prediction of drug synergy and accelerate the development of combination therapies for complex diseases.

22 Feb 2025

2024 CSCO Breast Cancer guidelines revolutionize treatment approaches in China

Breast cancer remains a major global health challenge, with treatment strategies varying widely across regions.

14 Feb 2025

Microbes in your gut could determine cancer treatment outcomes

Researchers reveal that gut microbiota influence the effectiveness of immune checkpoint inhibitors (ICIs) in cancer treatment, with specific bacterial strains enhancing or inhibiting anti-tumor immunity.

4 Feb 2025

Study uncovers two inhibitors to halt metaplastic breast cancer progression

A national study seeking more effective treatment for deadly metaplastic breast cancer has identified two inhibitor drugs with the potential to interrupt disease progression.

3 Feb 2025

Asymptomatic brain metastasis in stage 4 breast cancer requires reevaluation of screening guidelines

A new study led by researchers at Moffitt Cancer Center shows that asymptomatic brain metastasis is more common in stage 4 breast cancer patients than previously believed.

28 Jan 2025

Early detection of breast cancer proven cost-effective for Canada's health care system

Cancer screening is key to saving patients' lives since an earlier stage diagnosis improves survival rates, decreases morbidity, and leads to less intensive treatments.

7 Jan 2025

Study uncovers how cancer builds molecular bridges to evade the immune system

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War.

23 Dec 2024

Breakthrough study unravels molecular subtypes of breast cancer

Breast cancer, with its myriad subtypes, has long eluded a uniform treatment strategy. The disease's molecular complexity has rendered traditional, blanket treatments insufficient, particularly for the aggressive triple-negative form.

18 Dec 2024

New molecular imaging agent can accurately identify crucial cancer biomarker

A new molecular imaging agent can accurately identify a crucial biomarker found among many different types of cancer.

18 Dec 2024

A new era of targeted therapy with antibody–drug conjugates

TBC

From Sino Biological Inc. 16 Dec 2024

Targeted gene therapy shuts down cancer cells' energy centers

Researchers are shining a light on cancer cells' energy centers – literally – to damage these power sources and trigger widespread cancer cell death.

14 Dec 2024

Risk-reducing surgeries provide benefits for young BRCA-mutation carriers

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing salpingo-oophorectomy (RRSO) had lower rates of recurrence, secondary breast and/or ovarian malignancies, and death than those who did not undergo these surgeries, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Olaparib provides survival benefits for high-risk BRCA-positive breast cancer patients

Patients with high-risk, BRCA-positive breast cancer who received olaparib (Lynparza) after standard treatment continued to have better survival outcomes than those who received placebo after a median follow-up of 6.1 years, according to the latest results from the phase III OlympiA clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

11 Dec 2024

Spatial transcriptomics uncovers new treatment paths for triple-negative breast cancer

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative breast cancer (TNBC). The findings identify nine spatial archetypes and gene signatures linked to immunotherapy response and patient outcomes.

2 Dec 2024

AI models redefine TIL scoring in breast cancer but face challenges in real-world validation

AI models analyzing tumor-infiltrating lymphocytes show promise in predicting outcomes for triple-negative breast cancer, but external validation reveals critical performance gaps.

21 Nov 2024

Study shows AI can predict prognosis in triple-negative breast cancer

Researchers at Karolinska Institutet in Sweden have investigated how well different AI models can predict the prognosis of triple-negative breast cancer by analyzing certain immune cells inside the tumor.

19 Nov 2024